Date Time
Passion for mentorship drives successful serial entrepreneur’s new venture with University of Alberta
When Christopher Micetich attended the University of Alberta in the 1980s, he figured he would be a natural fit in chemistry.
After all, in 1980 his father Ronald Micetich, a world-renowned medicinal chemist, joined the Faculty of Pharmacy and Pharmaceutical Sciences as an adjunct professor teaching and working on contract chemical synthesis that would eventually lead to the creation of Ronald’s joint venture company with a major Japanese company.
That company, SynPhar Laboratories, would eventually file more than 100 compositional matter patents, one of which—tazobactam, a beta lactamase inhibitor used in combination with antibiotics to increase their effectiveness—would go on to have annual sales of more than $1 billion.